2018
Intranasal delivery of antibodies bypasses the blood‐brain barrier and results in significantly higher central nervous system levels than systemic administration
Boroumand S, Kumar N, Lochhead J, Pizzo M, Nehra G, Thorne R. Intranasal delivery of antibodies bypasses the blood‐brain barrier and results in significantly higher central nervous system levels than systemic administration. The FASEB Journal 2018, 32: lb617-lb617. DOI: 10.1096/fasebj.2018.32.1_supplement.lb617.Peer-Reviewed Original ResearchBlood-brain barrierCentral nervous systemBlood-cerebrospinal-fluid barrierIntranasal deliveryDelivery of antibodiesCerebral blood vesselsIntranasal routePotential of intranasal deliverySystemic administrationPerivascular spacesCNS target sitesCentral nervous system levelBlood vesselsNervous system levelNon-invasive strategyOlfactory bulbIntact in vivoSystemic deliveryTransports IgGPassive immunotherapyTreatment of neurological diseasesIgG transportCranial nervesQuantitative distribution studiesTherapeutic strategies
2012
A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets
Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN. A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets. Molecular Cancer Therapeutics 2012, 11: 2169-2173. PMID: 22863609, DOI: 10.1158/1535-7163.mct-12-0476-t.Peer-Reviewed Original ResearchConceptsBispecific antibodiesBispecific single-chain Fv fragmentsMonoclonal antibody 3G5Cancer therapyDelivery of antibodiesIntracellular targetsMolecular therapyTherapeutic useTherapeutic regulationMonoclonal antibodiesTherapyAntibodiesMAb 3E10Single-chain Fv fragmentInhibits growthP53 levelsImportant targetMDM2Limited accessFv fragmentTargetTumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply